Triptorelin: cancer uses and safety

by

Clinic-administered triptorelin, a gonadotropin-releasing hormone (GnRH) agonist, suppresses sex hormones. Overview.

Key takeaways
  • Check product.
  • Follow urgent warnings.
  • Licensing cannot prove independent superiority/equivalence.

Table of contents

Evidence summary

Clinical descriptions, care guidance and independently established treatment outcomes have different evidentiary roles. The table identifies what the reviewed sources can support and which financial or clinical questions remain unresolved.

Question / approach Evidence reviewed Funding / conflicts Interpretation / limits
Licences UK; US Producers Legal/safety context.
TEXT/SOFT 2014 original Public/group and manufacturer support Sponsored strategy trials; no brand-superiority claim.
Supplement replacement Safety context Public education; trial chains unclosed No independently cleared supplement replacement established here.
Prescribing PCA; Methods Allocation unclosed Items; no patient/global ranking.

Licences

UK Decapeptyl 22.5 mg: intramuscular prostate/precocious-puberty depot; no breast licence. Product.

UK Gonapeptyl Depot 3.75 mg contains acetate in a prefilled presentation, with subcutaneous or deep intramuscular administration. Its prostate and noncancer indications have their own specialist requirements. A shared ingredient does not make routes interchangeable. Gonapeptyl.

Ipsen’s current UK 11.25 mg notice records an acetate-to-pamoate change and asks users to consult the matching documents. The notice does not establish which formulation a particular clinic has in stock. Salt notice.

US Trelstar treats advanced prostate cancer. Licence.

US Triptodur is a separate paediatric product for central precocious puberty from age two; that licence is not an adult oncology instruction. Triptodur boundary.

UK Salvacyl has a psychiatrist-led indication for severe sexual deviations in adult men, combined with psychotherapy. It explains why some prescribing items are nononcology; this article provides no psychiatric treatment plan. Salvacyl scope.

Mechanism

GnRH agonists initially raise testosterone before suppressing it, potentially worsening prostate symptoms. Antagonists work differently without this initial flare; mechanism alone does not select treatment. Mechanism.

Before menopause, the ovaries are a main oestrogen source. Medical ovarian suppression reduces this supply; surgery to remove the ovaries is permanent. Aromatase inhibitors in premenopausal breast cancer require ovarian suppression. This is cancer endocrine treatment, not menopausal hormone replacement. Adjuvant treatment means treatment after surgery. Ovarian suppression.

Cancer pathways

Stage determines prostate care: hormone suppression may accompany local treatment or other systemic medicines. Metastatic care can require additional hormone therapy or chemotherapy, rather than an injection alone. Care.

UK Decapeptyl 3 mg permits adjuvant tamoxifen/aromatase-inhibitor combination for endocrine-responsive early breast cancer, high recurrence risk and confirmed premenopause after completed chemotherapy. Confirm ovarian suppression hormonally before/during aromatase inhibitors. Licence.

Supplements and supportive care

Supplements can interact with medicines, and ingredient amounts or quality may vary. Bring their names and labels to the cancer team rather than using a “hormone balance” or testosterone-promoting product to counter treatment. This review establishes no independently cleared supplement replacement for prescribed cancer therapy. Supplement safety.

Complementary care means support alongside conventional treatment. It must not postpone cancer care or become an alternative claimed cure. NCCIH discusses symptom-management approaches, but their underlying trial finances were not cleared here, so this guide does not rank them for triptorelin symptoms. Complementary care.

Tell the team which symptoms affect sleep, food, movement, work or relationships, and what help you need. Request a practical plan you can follow, including whom to contact when that plan is insufficient.

Evidence limits

The 2014 TEXT/SOFT report studied breast endocrine strategies, not universal superiority of one brand. TEXT used triptorelin; SOFT allowed different ovarian-suppression methods. Ipsen and Pfizer supported the work and donated drugs; manufacturer employees participated in the steering committee. Named author commercial ties were disclosed. These sponsored outcomes are excluded from this guide’s independent efficacy verdict. Original trial provenance.

Funding never overrides clinical instructions.

Safety

Hot flushes, sexual changes, fatigue, sleep/mood difficulties and bone loss can occur. Report worsening depression promptly, including suicidal thoughts, and seizures immediately, even without a seizure history. Warnings.

Sudden throat, tongue or lip swelling, breathing or swallowing difficulty, or collapse may be anaphylaxis. Get immediate emergency help; the UK emergency number is 999. Do not wait for the next injection appointment. Emergency allergy guidance.

With current or previous cancer, new limb weakness, walking difficulty, numbness, or bladder/bowel dysfunction can signal spinal cord compression. NICE treats this as an oncological emergency requiring immediate clinical contact. New progressive or unremitting back pain warrants specialist advice within 24 hours. Cord-compression guidance.

US label: fever/flu-like illness with progressive rash, mouth lesions or swollen glands needs urgent care. Clinicians interrupt suspected severe cutaneous reactions; confirmed reactions or grade-4 skin toxicity require permanent discontinuation. Do not attempt depot removal. Skin warning.

If someone cannot stay safe, has seriously injured themselves or has taken an overdose, seek immediate emergency help. Urgent mental-health deterioration without immediate danger still needs urgent professional advice. Crisis routes.

Chest pain, breathlessness, fainting or stroke-like speech/one-sided weakness require immediate medical assessment or emergency care. Emergency symptoms.

Sudden severe headache, vomiting or vision problems can signal rare pituitary apoplexy and need urgent assessment. Pituitary warning.

Interactions

Review QT-prolonging combinations, including certain antiarrhythmics, methadone, moxifloxacin and antipsychotics. UK Decapeptyl 11.25 mg says not to co-prescribe prolactin-raising drugs; pituitary-gonadotropin medicines require caution and hormone monitoring. Ask a pharmacist to review your list. Interactions.

Bring prescription/OTC/supplement details and planned changes; tell laboratory staff triptorelin can affect hormone tests. List/tests.

Companion breast medicines need their own review: some antidepressants and other medicines can reduce tamoxifen’s effectiveness. That is a tamoxifen interaction, not proof that every antidepressant interacts identically with triptorelin. Coordinate any proposed change with the oncology team. Companion medicine context.

Pregnancy and feeding

UK Decapeptyl prohibits pregnancy/feeding: exclude pregnancy, use nonhormonal contraception until periods resume. Absent periods after chemotherapy do not prove menopause. Precautions.

Do not use Decapeptyl with allergy to GnRH analogues or its ingredients. Mention previous injection reactions and anticoagulants, which can increase intramuscular bruising. Allergy and bleeding precautions.

UK Decapeptyl remains contraindicated in pregnancy/feeding. UK licence.

US Trelstar: female use and human milk/infant/production data are unestablished. Clinicians decide whether to discontinue feeding or treatment. US label.

Baseline review should address osteoporosis risk, diabetes/metabolic and cardiovascular disease, seizure or depression history and threatened urinary obstruction or vertebral disease. Follow-up may include bone assessment, blood pressure, glucose, cholesterol and disease/hormone measurements. The UK warning does not establish that every cardiovascular event was caused by triptorelin. Individual risk review.

Follow-up

Trelstar strengths release differently and are not additive; clinicians select the schedule. Formulation.

For suspected overdose, contact poison services promptly; collapse, seizure, breathing difficulty or inability to awaken requires immediate emergency help. Overdose guidance.

After a missed appointment, contact the provider immediately. Do not double or self-inject. Appointments.

During aromatase-inhibitor treatment, do not interrupt suppression without oncology coordination: oestrogen can rise. Report bleeding. Continuity.

Dizziness, sleepiness or visual problems can impair driving and machinery use. The Gonapeptyl label supplies no fixed time after injection that guarantees safety. Ask about your symptoms, other medicines and local driving rules. Driving caution.

Preclinical limits

UK animal pituitary findings have unknown clinical relevance: they cannot establish a human cancer-risk rate or treatment benefit. Preclinical limits.

Laboratory mechanisms and hormone reduction are not patient outcomes. Animal, in-vitro and sponsored findings cannot establish an independent human efficacy ranking.

Funding and source roles

Follow the money

Research funding at a glance

Funding & backersSource & studyClaim & limits

37 disclosure entries. The counts below summarize independence tiers explicitly assigned in this article. They count disclosures, not studies, funding amounts or evidence quality.

Tier 10Reported independence
Tier 27Indirect ties
Tier 312Interested party
Tier 418Self-interested

Consult this article’s source and funding notes for named funders, countries, relationships and exceptions where available. Institutional backing, researcher interests and trial sponsorship are separate questions. Public funding alone does not establish independence; commercial ties alone do not prove a claim false. This overview is not a new financial audit.

Funding cannot establish article/trial payments or independent efficacy.

Source Funding / backers Country / jurisdiction Independence Credibility / incentives / possible bias / gaps
Decapeptyl 3 mg SmPC Ipsen. London, UK Tier 4 D. Regulatory duties; sales bias.
Decapeptyl 3 mg leaflet Ipsen; manufacture: Signes. UK licence; France manufacture Tier 4 D. Required instructions; sales bias.
Decapeptyl 11.25 mg SmPC Ipsen. London, UK Tier 4 D. Regulatory duties; sales bias.
Decapeptyl 22.5 mg SmPC Ipsen. London, UK Tier 4 D. Regulatory duties; sales bias possible; trial finances unclosed.
Ipsen salt-change notice Ipsen notice. London, UK Tier 4 D. Notice accuracy; seller bias; transition/stock unclosed.
Gonapeptyl Depot SmPC Ferring licence-holder text. UK licence Tier 4 D. Regulated label; sales bias; formal interaction studies absent.
Salvacyl SmPC Ipsen. London, UK Tier 4 D. Regulatory duties; sales bias possible.
Trelstar US prescribing information Verity distributor; Debiopharm manufacturer. Ewing, US; Martigny, Switzerland Tier 4 D. Regulated label; sales bias; NLM hosting cannot establish independence.
Triptodur US prescribing information Azurity distributor; Debiopharm manufacturer. Woburn, US; Martigny, Switzerland Tier 4 D. Regulated paediatric label; sales bias; no adult indication.
AHFS triptorelin information ASHP publisher; NLM host. Bethesda, US Tier 3 C provisional. Reference review; publisher commercial bias possible; author/monograph payments and trial chains unclosed.
NCI prostate hormone therapy Federal institution; page-specific author/trial allocation unclosed. Bethesda, US Tier 2 C provisional. Clinical-review duties; institutional selection bias possible; author/trial interests unclosed.
NCI breast hormone therapy Federal institution; page-specific author/trial allocation unclosed. Bethesda, US Tier 2 C provisional. Clinical-review duties; institutional selection bias possible; no triptorelin licence/independent effect estimate.
NCCIH supplement safety Public institute; named staff reviewed 2019 update, outside interests unclosed. Bethesda, US Tier 2 C provisional. Staff review; institutional/reviewer bias possible; January 2019 footer/later references; trial finances unclosed.
NCCIH complementary cancer care Public institute; named NCI/NCCIH reviewers, private interests unclosed. Bethesda, US Tier 2 C provisional. Named reviewers; institutional/reviewer bias possible; October 2021 education; intervention finances unclosed.
NHS anaphylaxis National public clinical content; exact page allocation unclosed. England, UK Tier 2 C provisional. Clinical-review duties; institutional/contributor bias possible; June 2026 review overdue.
NHS urgent mental health help National public clinical content; exact page allocation unclosed. England, UK Tier 2 C provisional. Clinical-review duties; institutional/contributor bias possible; April 2026 review overdue.
NICE NG234 recommendations Public guideline body; committee interests and exact NG234 allocation unclosed. England, UK Tier 3 C provisional. Guideline scrutiny; institutional/committee bias possible; committee/allocation unclosed; fees cannot prove recommendation sponsorship.
England PCA 2025/26 NHSBSA; dataset/contributor payments unclosed. England, UK Tier 2 B provisional. Statistical transparency; administrative selection bias possible; no patient/global/efficacy inference.
PCA June 2026 methodology NHSBSA; contractor interests unclosed. England, UK Tier 3 B provisional. Methods transparency; method selection bias possible; no clinical outcomes.
NHSBSA 2025/26 accounts DHSC/Parliament; service charges/public repayment work. Newcastle upon Tyne, UK Tier 3 B provisional. Accounting duties; self-report bias possible; selected notes 1.1–1.2; PCA payments/interests unclosed.
2014 TEXT/SOFT original IBCSG/NCI; Ipsen/Pfizer support/donated drugs; maker steering employees; author commercial ties. International; Swiss coordinating group Tier 4 D. Disclosure duties; sponsor bias; direct failure; ranking excluded.
Ipsen 2025 registration document Drug sales; dated Beaufour–Schwabe/public float, bonds, bank credit, commercial paper. France; Luxembourg holdings Tier 4 D. Filing duties; issuer bias possible; backers, product/author payments unclosed.
Verity–Debiopharm 2020 agreement Companies announced extendable exclusive US commercialization; sales/licensing interests. US; Switzerland Tier 4 D. Joint-announcement accuracy incentive; seller bias; current contract/receipts/ultimate owners unclosed.
Verity current contact Seller self-identification. Ewing, New Jersey, US Tier 4 D. Contact accuracy incentive; seller bias; owners/capital/debt unclosed.
Debiopharm leadership biography Own biography links Thierry Mauvernay to privately owned Après-demain parent and family drug business. Switzerland Tier 4 D. Biography accuracy incentive; seller bias; indexed/direct failure; capital/receipts/product allocation unclosed.
Ferring 2025 results Privately owned drug business reports pharmaceutical revenue. Saint-Prex, Switzerland Tier 4 D. Corporate-disclosure incentive; seller bias; 10 March 2026 indexed/direct failure; current capital chain unclosed.
Ferring 2024 equity note Entire capital attributed to Ferring Foundation BV; ultimate Dr Frederik Paulsen Foundation at 31 December 2024. Swiss group; holding domicile unclosed Tier 4 D. Equity-disclosure incentive; company bias; indexed note 20/direct PDF failure; current ownership/donation independence unestablished.
Azurity 2021 acquisition announcement 2021: NovaQuest Private Equity then-majority owner; announced Arbor acquisition from JW Asset Management/KKR, conditional on regulatory approval; JPMorgan Chase Bank, N.A. and Truist Securities, Inc. financing sources for the transaction for Azurity. US Tier 4 D. Announcement accuracy incentive; seller bias; indexed/direct failure; completion/current owners/debt/product payments unclosed.
ASHP 2026 Treasurer report Program/products/services revenue and investments; building-sale reserves separate. Bethesda, US Tier 3 B provisional. Finance-disclosure duties; publisher commercial bias possible; 2025 actual/2026 projected/2027 budget differ; monograph allocation unclosed.
ASHP licensing AHFS database/AI licences and vendor, health-system and PBM partnerships. Bethesda, US Tier 4 D. Service-description accuracy incentive; sales bias; contract/monograph payments unclosed.
ASHP historical corporate support June 2019–May 2020 list includes Ferring and Pfizer. Bethesda, US Tier 3 C provisional. Support disclosure; historical self-report bias possible; current donations/page funding unclosed.
NCI current budget Congressional appropriations; FY2026 enacted differs from requests. Bethesda, US Tier 3 B provisional. Congressional scrutiny; institutional selection bias possible; 14 May 2026 update; page/author/trial allocation unclosed.
NCI Gift Fund Gifts supplement appropriations; mission-based research designation allowed. Bethesda, US Tier 3 B provisional. Gift-process accountability; donor-designation bias possible; 27 August 2025 update; donors/page allocations unclosed.
NCCIH appropriation history Congressional appropriations; displayed history ends FY2024. Bethesda, US Tier 3 B provisional. Appropriation transparency; institutional reporting bias possible; FY 2024 history, not current FY 2026/trial clearance.
NCCIH donation authority Conditional/unconditional gifts and bequests alongside appropriations. Bethesda, US Tier 3 B provisional. Gift-process accountability; donor-designation bias possible; donors/page payments/reviewer interests unclosed.
National NHS content policy DHSC funding; policy states no advertising/corporate sponsorship. England, UK Tier 3 C provisional. Clinical sign-off/interests policy; institutional/contributor bias possible; October 2022 policy overdue; individual declarations unverified.
NICE 2025/26 accounts DHSC grant-in-aid plus technology-appraisal/advice fees, research and licence income. Manchester, UK Tier 3 B provisional. Accounting duties; institutional self-report bias possible; selected note 6/funding policy; NG 234/committee allocation unclosed.

Frequently asked questions

Is triptorelin chemotherapy? It suppresses hormones; cancer care may also require other medicines or local treatment. Care.

What does the UK salt-change notice mean? The 11.25 mg notice records acetate changing to pamoate. Check your pack’s ingredient and matching leaflet with the clinic; the notice does not verify local stock. Notice.

Why can symptoms worsen initially? An early hormone rise can precede suppression. Report worsening symptoms immediately, particularly neurological or urinary problems. Flare.

What if my injection is late? Call the provider right away; do not calculate a replacement yourself. Advice.

Will hormones and fertility always recover? Testosterone recovery can be incomplete, especially after longer treatment or in older men. Discuss individual fertility and recovery expectations. Recovery.

Sources and funding notes

England 2025/26 items: 86,326 Triptorelin-coded; 28,133 embonate; 19,926 acetate. No pooling. PCA.

Triptorelin-coded items include 27 Salvacyl items; its psychiatric licence prevents cancer-only counts. Items; Licence.

Community items exclude hospital-pharmacy dispensing; they are not patient counts or global popularity. Methods.

NHSBSA routes: PCA-specific payments and full audit unclosed. Accounts.

Indexed/selected: stock, private payments, ultimate backers and trial chains unclosed.

  1. Decapeptyl 3 mg SmPC — Revised 1 June 2026.
  2. Decapeptyl 3 mg leaflet — Revised May 2026; posted 2 June.
  3. Decapeptyl 11.25 mg SmPC — Revised 1 June 2026.
  4. Decapeptyl 22.5 mg SmPC — Posted 8 June 2026.
  5. Ipsen salt-change notice — Current acetate-to-pamoate notice; use matching documents.
  6. Gonapeptyl Depot SmPC — Posted 20 October 2025; formulation, driving and pituitary tests.
  7. Salvacyl SmPC — Revised 9 June 2025; nononcology identity only.
  8. Trelstar US prescribing information — June 2026 revision; prostate indication and skin warning.
  9. Triptodur US prescribing information — September 2025 revision; CPP identity only.
  10. AHFS triptorelin information — Revised 15 January 2026; practical/emergency advice.
  11. NCI prostate hormone therapy — Reviewed 4 October 2024; mechanism and contemporary pathway.
  12. NCI breast hormone therapy — Updated 23 September 2026; hormone receptors and ovarian suppression.
  13. NCCIH supplement safety — Interactions and supplement safety, not cancer efficacy.
  14. NCCIH complementary cancer care — Supportive versus alternative care boundary.
  15. NHS anaphylaxis — Immediate emergency allergy action.
  16. NHS urgent mental health help — Immediate danger and urgent crisis routes.
  17. NICE NG234 recommendations — New cord-compression symptoms require immediate clinical contact.
  18. England PCA 2025/26 — 4 June 2026; Tables 7/8.
  19. PCA June 2026 methodology — BNF.
  20. NHSBSA 2025/26 accounts — Selected notes.
  21. 2014 TEXT/SOFT original — Population and commercial provenance, not brand superiority.
  22. Ipsen — Selected capital/debt, 31 December 2025.
  23. Verity–Debiopharm 2020 agreement — Dated rights context, no stock or exclusive-current-rights claim.
  24. Verity current contact — Current distributor location, not financial clearance.
  25. Debiopharm leadership biography — Selected parent/leadership identity, not a private-ledger audit.
  26. Ferring 2025 results — Dated corporate revenue route only.
  27. Ferring 2024 equity note — Historical beneficial-owner trail only.
  28. Azurity 2021 acquisition announcement — Historical commercial backers, not present cap-table proof.
  29. ASHP 2026 Treasurer report — Publisher finances, not author or efficacy clearance.
  30. ASHP licensing — Publisher revenue incentive only.
  31. ASHP historical corporate support — Dated institutional commercial route only.
  32. NCI current budget — Public institutional finance only.
  33. NCI Gift Fund — Private gift authority, not proof of a named page sponsor.
  34. NCCIH appropriation history — Institute-specific public funding route.
  35. NCCIH donation authority — Institute-specific private gift route.
  36. National NHS content policy — National content process; not individual provider accounts.
  37. NICE 2025/26 accounts — Own institutional mixed routes, not guideline sponsorship proof.

Educational research reviewed 5 October 2026. Diagnosis and treatment require a qualified clinician; this article does not provide an individual prescription or replace urgent assessment.

Have a question — or want us to cover something?

Ask about anything on this page, or request the next deep dive: an ingredient, a supplement, or a health concern. We use published research, evidence syntheses, and regulatory guidance, with clear source links.

We store your topic, message, optional email, and this page so we can manage and reply to the request. Do not include diagnoses, medications, or other sensitive medical information. See our Privacy Policy.